Kazia Therapeutics (NASDAQ: KZIA)

Currency in USD

Last close As at 25/01/2023

USD0.96

−0.06 (−5.88%)

Market capitalisation

USD13m

Kazia Therapeutics is a late-stage clinical pharmaceutical company with lead asset paxalisib (a PI3K inhibitor that can cross the BBB, licensed from Genentech) in a pivotal study for GBM and in early-stage studies in childhood brain cancers, DIPG and AT/RT. The other asset is the Phase I drug EVT801, an inhibitor of VEGFR3.

GBM is the most common primary cancer of the brain with c 12,500–13,000 new cases reported in the United States per year. There are very limited treatment options for GBM and there is a very low survival rate. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment. EVT801 will target the multibillion-dollar angiogenesis cancer market.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Iain Ross

    Chairman

  • James Garner

    CEO

  • John Friend

    CMO

  • Karen Krumeich

    CFO

Balance Sheet

Forecast net debt (US$m)

9.9

Forecast gearing ratio (%)

145

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 76.5 (0.7) (85.5)
Relative 68.9 (4.5) (84.2)
52 week high/low US$8.4/US$0.5

Financials

Kazia Therapeutics has announced a research collaboration with QIMR Berghofer Medical Research Institute (an Australia-based cancer research center) to investigate the utility of its lead asset, paxalisib (PI3K/mTOR inhibitor) in solid tumors. The collaboration plans to build on previously conducted research, including the potential use of paxalisib as an immune modulator in solid tumors. We note that the company recently announced encouraging data in a preclinical melanoma study, highlighting Kazia’s growing focus on exploring indications other than brain cancer and brain metastases, following the recent setback in the GBM AGILE study where paxalisib was unsuccessful in graduation to stage 2 of the Phase III trial.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2021A 10.5 (3.1) (3.1) (0.25) N/A N/A
2022A 0.0 (14.6) (14.6) (1.08) N/A N/A
2023E 0.0 (18.6) (18.6) (1.12) N/A N/A
2024E 10.6 (16.8) (16.8) (1.01) N/A N/A

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free